BeyondSpring's second quarter 2026 net loss was $1.8 million as Phase 3 trial preparations continue

BeyondSpring reported a net loss from continuing operations of $1.8 million for the second quarter of 2026, as the company remains in a pre-revenue clinical stage. Management is prioritizing regulatory and manufacturing preparations for the DUBLIN-4 confirmatory Phase 3 trial in non-small cell lung cancer (NSCLC) following survival data presented at major conferences.

Key Highlights

• Research and development expenses remained flat at $1.0 million, with higher drug manufacturing costs offset by reduced personnel and professional service fees.
• Total liquidity declined as cash, cash equivalents, and short-term investments fell to $6.5 million from $12.6 million at the end of 2025.
• Clinical updates showed a 58% two-year overall survival rate in Phase 2 trials for Plinabulin used in metastatic NSCLC patients who progressed after initial immune checkpoint inhibitor therapy.